UBC Opens New Office in Tokyo
United BioSource Corporation (UBC; Bethesda, MD) announced the opening of its newest global office in Tokyo, Japan. The office will be led by Kumpei Kobayashi, PharmD, a biopharmaceutical industry veteran with over 20 years of product development experience throughout the Asia-Pacific region. Personnel in the new UBC office will support the company’s investigator training and certification solutions as well as ongoing clinical research monitoring services in the region.
“The UBC office in Tokyo will help us support our clients’ research projects with local personnel who understand the needs of patients, health care professionals and regulators in this important region. Local knowledge of the Asia-Pacific markets is absolutely essential when we help clients manage research projects that are often very large, complex and supported by significant financial investments,” said Catherine Spear, UBC’s Senior Vice President.
Dr. Kobayashi will be joined by several members of UBC’s management team, including David Miller, MD, who has served as a scientific leader on several Pan-Asian and multi-national studies involving sites in Japan, Taiwan, Korea, China, Hong Kong, India, Philippines, Singapore, and Thailand.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
